Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 09, 2022 07:40 ET | Source: InflaRx N.V.

InflaRx Initiates First-in-Human Study with Small Molecule C5aR Inhibitor INF904

Randomized, double-blind, placebo-controlled Phase I trial of orally administered complement inhibitor INF904 initiatedStudy designed as single ascending dose to determine safety, tolerability and...